GALXC Trademark

Trademark Overview

On Thursday, June 30, 2016, a trademark application was filed for GALXC with the United States Patent and Trademark Office. The USPTO has given the GALXC trademark a serial number of 87089769. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 29, 2021. This trademark is owned by Dicerna Pharmaceuticals, Inc.. The GALXC trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:

Biologic preparations for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases and viral infections; Biological compound in the form of a molecular complex that acts as a platform for the delivery of RNA-based drugs to biological cells; and drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies

custom manufacture of oligonucleotides

research and development of anti-cancer drugs and anti-cancer preparations; research and development of pharmaceutical products
galxc

General Information

Serial Number87089769
Word MarkGALXC
Filing DateThursday, June 30, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 29, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, December 26, 2017

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of a stylized version of the term "GALXC".
Goods and ServicesBiologic preparations for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases and viral infections; Biological compound in the form of a molecular complex that acts as a platform for the delivery of RNA-based drugs to biological cells; and drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
Goods and Servicescustom manufacture of oligonucleotides
Goods and Servicesresearch and development of anti-cancer drugs and anti-cancer preparations; research and development of pharmaceutical products

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 5, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateTuesday, July 5, 2016
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 5, 2016
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDicerna Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421
Party NameDicerna Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events

Event DateEvent Description
Monday, March 29, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 29, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 25, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 25, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 25, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, August 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 21, 2020EXTENSION 5 GRANTED
Wednesday, August 12, 2020EXTENSION 5 FILED
Tuesday, August 18, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 12, 2020TEAS EXTENSION RECEIVED
Saturday, February 15, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 13, 2020EXTENSION 4 GRANTED
Thursday, February 13, 2020EXTENSION 4 FILED
Thursday, February 13, 2020TEAS EXTENSION RECEIVED
Wednesday, August 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 12, 2019EXTENSION 3 GRANTED
Monday, August 12, 2019EXTENSION 3 FILED
Monday, August 12, 2019TEAS EXTENSION RECEIVED
Monday, June 10, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 10, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, January 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 10, 2019EXTENSION 2 GRANTED
Thursday, January 10, 2019EXTENSION 2 FILED
Thursday, January 10, 2019TEAS EXTENSION RECEIVED
Wednesday, August 22, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 20, 2018EXTENSION 1 GRANTED
Monday, August 20, 2018EXTENSION 1 FILED
Monday, August 20, 2018TEAS EXTENSION RECEIVED
Monday, July 23, 2018TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, February 20, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 26, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 26, 2017PUBLISHED FOR OPPOSITION
Wednesday, December 6, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 17, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 2, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 2, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 2, 2017TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, May 3, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, May 3, 2017FINAL REFUSAL E-MAILED
Wednesday, May 3, 2017FINAL REFUSAL WRITTEN
Tuesday, April 11, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 10, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 10, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 11, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 11, 2016NON-FINAL ACTION E-MAILED
Tuesday, October 11, 2016NON-FINAL ACTION WRITTEN
Tuesday, October 11, 2016ASSIGNED TO EXAMINER
Friday, July 15, 2016TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Friday, July 15, 2016TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, July 5, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, July 4, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

galxc pharmaceutical diseases delivery research based biological development anti preparations therapies